Sodium-glucose cotransporter 2 inhibitor Dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity

Background

Anthracycline-mediated adverse cardiovascular events are among the leading causes of morbidity and mortality in cancer patients. Cardioprotective strategies in primary and secondary prevention are still needed in clinical practice to improve cancer patient survival an to avoid drug therapy discontinuation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors exerts multiple cardiometabolic benefits in patients with/without type 2 diabetes, chronic kidney disease, and heart failure with reduced ejection fraction. We hypothesized that Dapagliflozin, administered before and during doxorubicin therapy, could improve cardiac function and reduce pro-necrotic pathways in preclinical models

Methods

Female C57Bl/6 mice were untreated (Sham, n=6) or treated for 10 days with doxorubicin i.p at 2.17 mg/kg (DOXO, n=6), DAPA at 12 mg/kg (DAPA, n=6) or doxorubicin combined to DAPA (DOXO-DAPA, n=6). Ejection fraction, radial and longitudinal strain were analyzed through transthoracic echocardiography (Vevo 2100). Cardiac tissue expression of NLRP3 inflammasome, Myd88, DAMPs (galectine 3 and calgranulinS100) and systemic chemokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL17-α, IL-18, IFN-γ, TNF-α, G-CSF, and GM-CSF) were quantified through ELISA methods. Immunohistochemical stains (IHC) of NF-kB was performed in heart and kidney tissues.

Results

DAPA improved significantly the EF and prevented the reduction of radial and longitudinal strain after 10 days of treatment with doxorubicin. A reduced expression of NLRP3, MyD88, DAMPs and NF-kB in cardiac tissues was seen in DOXO-DAPA group compared to DOXO mice (p<0.001). Systemic expression of IL-1β, IL-6, TNF-α, G-CSF and GM-CSF were significantly reduced after treatment with DAPA indicating anti-inflammatory properties. Plasma levels of Calgranulin S100 and galectine-3 were strongly enhanced in DOXO group; on the other hand their expression were reduced in DAPA-DOXO group (p<0.005). Immunohistochemical stains (IHC) reveal reduction NF-kB expression in myocardial and renal tissue in DOXO-DAPA vs DOXO group. 

Conclusion

DAPA is able to improve cardiac function and reduce biomarkers involved in heart failure and fibrosis. IHC analysis clearly indicates anti-inflammatory properties of DAPA in cardiac and renal tissues. The overall picture of the study pushes the use of DAPA in primary prevention of cardiomyopathies induced by anthracyclines in cancer patients.